This market research report on ADME/Tox Technologies covers both products and services used in the ADME/TOX industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology. The research report serves as a guide to ADME/Tox industry, covering 341companies that are engaged in ADME/Tox studies/screening, products and services. Major Contract Research Organizations serving ADME/Tox industry are also covered in the corporate directory section of this research report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 145 exclusive graphically represented exhibits.

Download the short sample report.

Download the table of contents in PDF format

Time and Money - both can be saved by applying ADME/Tox technologies in the early drug discovery processes. ADME/Tox studies determine dosage and toxicity issues for any new drug before human trials. Most of the drugs fail in the clinical development phase due to their poor ADME/Tox properties. Companies are making robust efforts in eliminating poor elements before they enter into clinical trials. Drug failure in or post clinical trial phase may lead the company into economic disasters.

The global ADME/Tox market is projected to reach US$ 4.4 billion by 2012. Asia Pacific and Latin America are the emerging markets for clinical trials after the US, Canada and Europe. Contract Research Organizations (CROs) from across the globe, especially from the US and Europe, are establishing their facilities for clinical trials in these regions. With lot of support from government and numerous collaborations with government institutions and laboratories by industry giants including Becton Dickinson, GlaxoSmithKline and Corning, Singapore and Hong Kong are emerging as promising markets making Asia-Pacific the fastest growing ADME/Tox market during 2005-2012.

Toxicity profiles of drugs can now be studied very early in developmental stages courtesy the evolving ADME/Tox tools market. The technological improvements have time and again demonstrated that no single drug reacts in the same manner across all demographic profiles of humankind such as the aged population, the middle aged ones, adolescents, and children. Also, human mind conditions are an important criterion as mentally ill people react differently from the normal people. Pathbreaking developments in bioanalytical technology include High Pressure Liquid Chromatography (HPLC), radioimmunoassays, mass spectrometry, and genetic engineering.

Prediction of potential human risks of a new drug candidate is crucial in early stages of the drug discovery/development process. Even 10%-12% increase in identifying failures before a drug candidate entering the clinical trial stage could save the company over US$100 million. Identification of numerous biological pathways and networks that pose potential targets for the treatment of disease is driven by latest technologies for understanding disease’s molecular mechanism and by the completion of Human Genome Project. This phenomenon created hopes for increased number of new molecule entities to obtain approval from regulatory authorities. In fact, most of the candidate drugs are failing at clinical testing phase due to poor pharmacokinetic (ADME) properties, non-efficacy and toxicity.

The pharmaceutical industry is on the cutting edge of change. The industry is constantly under pressure to develop new products for the medical industry and of course also to earn profits. The federal regulatory systems order very high standards for benchmarking successful drugs before final approval. Companies that produce state-of-art tools and focus on complete solutions will be clear winners. Automation is the way to go with emphasis on lower costs. Clearly, animal models cannot be totally overruled owing to traditional concerns, and also the comfort level involved since they provide the closest biological environment to human systems.

- Accelrys, Inc. (USA)
- ADMET Technologies (USA)
- Advanced Chemistry Development, Inc. (ACD/Labs) (Canada)
- Agilent Technologies, Inc. (USA)
- AMRI Hungary, Inc. (Hungary)
- Applied Biosystems Group (USA)
- Argenta Discovery Ltd. (UK)
- ArQule, Inc. (USA)
- Aureus Pharma (France)
- Bayer Technology Services GmbH (Germany)
- BD Biosciences (USA)
- Biacore International AB (Sweden)
- Bio-Rad Laboratories, Inc. (USA)
- Bridge Pharmaceuticals (USA-China)
- Caliper Life Sciences, Inc. (USA)
- Cellomics, Inc. (USA)
- Celsis International plc (UK)
- Cerep SA (France)
- Charles River Laboratories, Inc. (USA)
- ChemSilico LLC (The) (USA)
- Chenomx, Inc. (Canada)
- CompuDrug International, Inc. (USA)
- Cyprotex plc (UK)
- Elsevier MDL (USA)
- Gene Logic, Inc. (USA)
- Iconix Pharmaceuticals, Inc. (USA)
- ID Business Solutions Ltd. (UK)
- Invitrogen, Inc. (USA)
- Kendle International, Inc. (USA)
- Kibron, Inc. (Finland)
- LHASA Ltd. (UK)
- LION biosciences AG (Germany)
- Millipore Corporation (USA)
- Molecular Discovery Ltd. (UK)
- MultiCASE, Inc. (USA)
- Noray Bioinformatics S.L. (Spain)
- Perkin Elmer, Inc. (USA)
- Pharma Algorithms (Canada)
- Phase-1 Molecular Toxicology (USA)
- Promega Corporation (USA)
- Qualyst, Inc. (USA)
- Ranbaxy Laboratories Ltd. (India)
- Schrodinger LLC (USA)
- Simulations Plus, Inc. (USA)
- Sirius Analytical Instruments Ltd. (UK)
- Stem Cell Innovations, Inc. (USA)
- Strand Life Sciences (India)
- Tecan AG (Switzerland)
- Thermo Fisher Scientific, Inc. (USA)
- Tripos, Inc. (USA)
- Waters Corporation (USA)
- Xceleron Ltd. (UK)

For those who are intrested to buy the report by chapter:

CHAPTER	TITLE	SHORT DESCRIPTION	PRICE (US$)
I	Scope and Methodology	Provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used. * Will be delivered free with purchase of any of the other chapters mentioned below.	FREE*
II	Report Synopsis	Synopsis of the report summarizes the global market, by ADME/Tox Technologies - In vivo, In vitro and In silico. Global market is also analyzed by geographic regions including North America, Europe, Asia-Pacific and Rest of World. The chapter provides market values in US$ (2006, 2009, 2012) for each geographic region including the US , Canada , UK , Germany , France , Sweden , Finland , Italy , Japan , China , India , and Australia . A List of major companies by technology is also provided.	$1000
III	Product / Technology Research	This chapter gives an insight into ADME/Tox Technologies market including definitions, segmentation and applications. The chapter also provides market values in US$ (for the period 2005 through 2012) for ADME/Tox technologies by segment. Global HTS and Cell based Assay markets by services and geographic region are also analyzed. The chapter also includes product trends and potential opportunities. Various ADME/Tox Methods, Toxicity types, and the importance of ADME/Tox in pharmaceutical industry and drug discovery process, and the challenges faced by the industry are also discussed.	$800
IV	Market Dynamics	Market Dynamics chapter provides information on global markets for ADME/Tox Technologies. The chapter includes global market analysis (in US$) by geographic region; analysis of each region by both technology and product segment; a brief business profile of major global companies; and a report of corporate activities such as mergers and acquisitions, partnerships, new product developments/launches, etc. Global LIMS, HTS, Drug Discovery, Pharmaceutical Cell based Screening and Cell based Assay markets are also analyzed. The section includes key market trends and an industry outlook.	$1350
V	Corporate Directory	This chapter provides a global region-wise list of 341 companies, CROs and academic institutions that offer ADME / Tox products and/or services.	$300